Easton Pharmaceuticals, Inc. Patents
Drug Delivery Technology
In October of 2013, the company purchased 50% ownership of a drug to treat FSAD (Female Sexual Arousal Disorder). The drugs transdermal delivery technology is a safe, novel and proprietary drug delivery platform that has been developed based on years of research by various individuals to address many of the needs in the multi billion dollar drug delivery segment of the pharmaceutical market. The proprietary system used only in Femlife consists of a water based, complex polymer matrix, which includes methoxypolyethyleneglycol, hydroxyethylcellulose and carboxymethylcellulose. The FSAD Drug in 2008 underwent a clinical trial at Cedar Sinai Medical Center in Beverley Hills, CA. which was prematurely ended, but not known to be as a result of lack of efficacy but due to other reasons.
Included with the 50% ownership interest with the purchase of the FSAD Drug are the following patents or patent pendings.
The company through its acquisition and current 50% ownership of drug “Femlife” for the treatment of female sexual dysfunction, presently has patents and patent pendings.
Prior to the sale in its ownership interest in the L.A.M. IPM TM technology, in the fall of 2008, EASTON PHARMACEUTICALS, Inc. (formerly LAM) owned fifteen U.S. patents, nine foreign patents, five U.S. patent applications and numerous international patent applications designating over 100 foreign countries with claims relating to our sustained release delivery matrix system, systems containing drug preparations, uses of the systems for various treatment therapies and addiction therapeutic program. The patents were to expire between 2015 and 2018.